C

    Cullinan Oncology LLC (CGEM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.07
    +0.37 (+1.71%)

    Market Cap: $1.33B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(14/23)
    Avg Surprise
    -30.03%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.85
    Range$-1.04 - $-0.71
    9 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.87-2.4%
    60d ago$-0.86-1.7%
    30d ago$-0.86-1.7%
    7d ago$-0.86-1.1%
    Current$-0.85
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.62
    Range$-1.31 - $0.69
    9 analysts
    Revenue Consensus
    $14M
    Range$0 - $104M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.85---
    Jun 26
    		$-0.81$-0.71-14.08%Miss+24.3%
    Mar 26
    		$-0.75$-0.84+10.71%Beat-1.4%
    Dec 25
    		$-0.77$-0.87+11.89%Beat-5.5%
    Sep 25
    		$-0.77$-0.89+13.48%Beat-11.6%
    Jun 25
    		$-1.07$-0.83-28.92%Miss-42.7%
    Mar 25
    		$-0.74$-0.81+8.64%Beat+14.0%
    Dec 24
    		$-0.73$-0.74+1.66%Beat-35.2%
    Sep 24
    		$-0.69$-0.77+10.39%Beat+24.2%
    Jun 24
    		$-0.75$-0.73-2.74%Miss+8.5%
    Mar 24
    		$-0.86$-0.99+13.13%Beat+39.4%
    Dec 23
    		$-0.54$-0.98+44.90%Beat+8.5%
    Sep 23
    		$-0.91$-0.94+3.19%Beat-68.5%
    Jun 23
    		$-0.82$-1.00+18.00%Beat-121.8%
    Mar 23
    		$-1.42$-0.98-44.90%Miss-425.9%
    Dec 22
    		$-0.59$-0.71+16.90%Beat+20.3%
    Sep 22
    		$-0.54$-0.97+44.33%Beat-8.0%
    Jun 22
    		$3.77$5.42-30.44%Miss+1147.2%
    Mar 22
    		$-0.27N/A+50.91%Beat-15782.4%
    Dec 21
    		$-0.74$-0.47-57.45%Miss+74.1%
    Sep 21
    		$-0.50$-0.43-16.28%Miss-108.3%
    Jun 21
    		$-0.36$-0.42+14.29%Beat+64.6%
    Mar 21
    		$-0.00N/A-105.67%Miss+99.8%
    Dec 20
    		$-2.86$-0.38-652.63%Miss-261.8%
    Sep 20
    		$-0.24$0.00N/AMiss+75.2%
    Jun 20
    		$-1.02$0.00N/AMiss-20.7%
    Mar 20
    		$-0.79$0.00N/AMiss+6.3%
    Dec 19
    		$-0.79$0.00N/AMiss-
    Jun 19
    		$-0.97$0.00N/AMiss-
    Mar 19
    		$-0.84$0.00N/AMiss-
    Dec 18
    		$-0.84$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.12EV/EBITDA-1.46x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-50.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.42xQuick Ratio8.42x
    Trading Statistics
    Beta-0.02Avg Volume688.22K
    52-Week High$23.1952-Week Low$5.68

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$22.04
    SMA 20$20.47
    SMA 50$18.78
    SMA 200$14.35
    EMA 10$21.75
    EMA 20$20.77
    EMA 50$18.91
    EMA 200$14.87

    MACD

    Line: 1.26Signal: 1.18Hist: 0.07

    ADX

    ADX: 33.5+DI: 24.0-DI: 12.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$23.16

    Bollinger Bands

    Upper Band$24.21
    Lower Band$16.73
    %B Position3654%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    63.6

    Momentum Oscillators

    Stoch %K78.5
    Stoch %D85.8
    Williams %R-24.3
    ROC (10d)7.2%
    Momentum1.48
    CCI (20d)61.4
    MFI (14d)68.5

    Volatility Measures

    ATR (14d)$1.13(5.1%)
    StdDev (20d)1.87
    Hist Vol56.2%(High)

    Volume Flow

    VWAP$21.88
    OBV26.0M
    AD Line5.2M
    CMF (20d)0.212

    Volume Metrics

    Avg Vol (20d)703.3K
    Vol Ratio1.0x
    VWMA (20d)$20.48

    Pivot Points

    R3$23.85
    R2$23.36
    R1$22.53
    Pivot Point$22.05
    S1$21.22
    S2$20.73
    S3$19.90

    Advanced Oscillators

    TSI34.92
    Ultimate Osc56.6
    KST233.57

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$79,000$0$0$0$77,000$0$0$0$77,000$0
    Gross Profit$0$0$-79,000$0$0$0$-77,000$0$0$0$-77,000$0
    Operating Expenses$57.25M$53.70M$55.26M$55.59M$75.80M$55.00M$55.05M$48.85M$50.03M$42.99M$45.48M$44.80M
    R&D$44.44M$42.12M$42.95M$41.97M$61.03M$41.46M$40.49M$35.51M$36.26M$30.65M$34.85M$33.82M
    SG&A$12.82M$11.57M$12.31M$13.63M$14.77M$13.54M$14.56M$13.35M$13.77M$12.34M$10.64M$10.98M
    Operating Income$-57,254,000$-53,697,000$-55,259,000$-55,595,000$-75,798,000$-54,996,000$-55,048,000$-48,855,000$-50,027,000$-42,989,000$-45,485,000$-45,243,000
    Interest Income$3.65M$4.10M$4.62M$5.09M$5.92M$6.58M$7.51M$8.38M$8.07M$5.69M$5.92M$5.88M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-53,704,000$-49,661,000$-50,713,000$-50,610,000$-70,055,000$-48,501,000$-47,530,000$-40,560,000$-42,028,000$-37,340,000$-39,685,000$-39,183,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-53,704,000$-49,661,000$-50,713,000$-50,610,000$-70,055,000$-48,501,000$-47,647,000$-40,560,000$-42,028,000$-37,340,000$-25,563,000$-39,183,000
    EBITDA$-57,273,000$-54,457,000$-56,180,000$-56,982,000$-75,902,000$-57,316,000$-58,476,000$-53,795,000$-53,747,000$-46,263,000$-49,146,000$-44,983,000
    EBIT$-57,352,000$-53,759,000$-55,328,000$-55,703,000$-75,979,000$-55,081,000$-55,042,000$-48,944,000$-50,099,000$-43,033,000$-45,602,000$-45,063,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGEM

    News

    Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results

    Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive Phase 3 results for zipalertinib plus chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The REZILIENT3 trial met its primary endpoint of improved progression-free survival, positioning zipalertinib as a potential first-line oral therapy for this underserved patient population. The companies plan to seek U.S. regulatory approval and present full results at an upcoming medical conference.

    GeneOnline•8/21/26•
    Bullish

    Taiho, Cullinan trial results selected for lung cancer conference

    Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which evaluated zipalertinib plus chemotherapy for non-small cell lung cancer with EGFR exon 20 insertion mutations, met its primary endpoint of progression-free survival. The presentation will detail these findings at a Presidential Symposium in September 2026.

    Investing.com Nigeria•8/20/26•
    Bullish

    Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

    Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that data from their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) has been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The presentation will occur during the Presidential Symposium 2 and will detail the planned interim analysis results, which met the primary endpoint of progression-free survival. Zipalertinib is an investigational orally available small molecule designed to target activating mutations in EGFR, specifically exon 20 insertion mutations.

    Investing News Network•8/19/26•
    Bullish

    Cullinan's lung cancer trial met its main goal; results are set for presentation in September

    Cullinan Therapeutics (CGEM) announced that its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC met its primary endpoint of progression-free survival. The positive results have been selected for presentation at the Presidential Symposium 2 of the IASLC 2026 World Conference on Lung Cancer in September 2026. This trial evaluated zipalertinib in combination with chemotherapy against chemotherapy alone for patients with this specific type of non-small cell lung cancer.

    Stock Titan•8/19/26•
    Bullish

    UBS raises Cullinan Oncology stock price target to $27 on trial data

    UBS has increased its price target for Cullinan Oncology Inc. (NASDAQ:CGEM) to $27 from $24, while maintaining a Buy rating. This adjustment follows positive Phase 3 trial results for zipalertinib in treating first-line EGFR exon 20 insertion non-small cell lung cancer. The firm also raised the probability of success for zipalertinib in this indication to 85% from 40%, projecting significant peak sales potential.

    Investing.com•8/18/26•
    Bullish

    Frequently Asked Questions About CGEM

    Does CGEM pay dividends?
    Cullinan Oncology LLC (CGEM) does not currently pay a regular dividend.
    What is CGEM's market cap?
    Cullinan Oncology LLC (CGEM) has a market capitalization of $1.33B with a current stock price of $22.07.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In